{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:32:46Z","timestamp":1768642366210,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40273-016-0462-4","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T02:22:55Z","timestamp":1477534975000},"page":"177-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update"],"prefix":"10.1007","volume":"35","author":[{"given":"Spencer M.","family":"Vale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dane","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"issue":"1","key":"462_CR1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2133.2011.10337.x","volume":"165","author":"PH Youl","year":"2011","unstructured":"Youl PH, Janda M, Aitken JF, Del Mar CB, Whiteman DC, Baade PD. Body-site distribution of skin cancer, pre-malignant and common benign pigmented lesions excised in general practice. BrJ Dermatol. 2011;165(1):35\u201343.","journal-title":"BrJ Dermatol."},{"issue":"Suppl 66","key":"462_CR2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.0366-077X.2003.05621.x","volume":"149","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol. 2003;149(Suppl 66):31\u20133.","journal-title":"Br J Dermatol."},{"issue":"Suppl 2","key":"462_CR3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2133.2012.11085.x","volume":"167","author":"A Traianou","year":"2012","unstructured":"Traianou A, Ulrich M, Apalla Z, De Vries E, Bakirtzi K, Kalabalikis D, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012;167(Suppl 2):36\u201342.","journal-title":"Br J Dermatol."},{"issue":"1 Suppl 1","key":"462_CR4","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jaad.2012.10.001","volume":"68","author":"DS Rigel","year":"2013","unstructured":"Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S20\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"462_CR5","doi-asserted-by":"crossref","first-page":"22368","DOI":"10.5070\/D3204022368","volume":"20","author":"ET Landis","year":"2014","unstructured":"Landis ET, Davis SA, Taheri A, Feldman SR. Top dermatologic diagnoses by age. Dermatol Online J. 2014;20(4):22368.","journal-title":"Dermatol Online J."},{"issue":"1 Pt 2","key":"462_CR6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1067\/mjd.2000.103342","volume":"42","author":"SJ Salasche","year":"2000","unstructured":"Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"462_CR7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/archderm.1988.01670010036018","volume":"124","author":"A Engel","year":"1988","unstructured":"Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971\u20131974. Arch Dermatol. 1988;124(1):72\u20139.","journal-title":"Arch Dermatol."},{"issue":"8","key":"462_CR8","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2013.134","volume":"133","author":"SC Flohil","year":"2013","unstructured":"Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol. 2013;133(8):1971\u20138.","journal-title":"J Invest Dermatol."},{"issue":"4","key":"462_CR9","first-page":"201","volume":"87","author":"SR Feldman","year":"2011","unstructured":"Feldman SR, Fleischer AB Jr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011;87(4):201\u20137.","journal-title":"Cutis."},{"issue":"3","key":"462_CR10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archdermatol.2009.378","volume":"146","author":"RS Padilla","year":"2010","unstructured":"Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010;146(3):288\u201393.","journal-title":"Arch Dermatol."},{"issue":"8589","key":"462_CR11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","volume":"1","author":"R Marks","year":"1988","unstructured":"Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795\u20137.","journal-title":"Lancet."},{"issue":"11","key":"462_CR12","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","volume":"115","author":"VD Criscione","year":"2009","unstructured":"Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115(11):2523\u201330.","journal-title":"Cancer."},{"issue":"3","key":"462_CR13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bjd.12420","volume":"169","author":"RN Werner","year":"2013","unstructured":"Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169(3):502\u201318.","journal-title":"Br J Dermatol."},{"issue":"1","key":"462_CR14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00042728-200501000-00009","volume":"31","author":"GJ Chen","year":"2005","unstructured":"Chen GJ, Feldman SR, Williford PM, Hester EJ, Kiang SH, Gill I, et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg. 2005;31(1):43\u20137.","journal-title":"Dermatol Surg."},{"issue":"1 Suppl 1","key":"462_CR15","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2012.09.051","volume":"68","author":"RI Ceilley","year":"2013","unstructured":"Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S28\u201338.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"462_CR16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amepre.2014.08.036","volume":"48","author":"GP Guy Jr","year":"2015","unstructured":"Guy GP Jr, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the US, 2002\u20132006 and 2007\u20132011. Am J Prevent Med. 2015;48(2):183\u20137.","journal-title":"Am J Prevent Med."},{"issue":"9859","key":"462_CR17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"CJ Murray","year":"2012","unstructured":"Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197\u2013223.","journal-title":"Lancet."},{"issue":"9995","key":"462_CR18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"T Vos","year":"2015","unstructured":"Vos T, Barber R, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743\u2013800.","journal-title":"Lancet."},{"issue":"3","key":"462_CR19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1067\/mjd.2003.186","volume":"48","author":"TS Housman","year":"2003","unstructured":"Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48(3):425\u20139.","journal-title":"J Am Acad Dermatol."},{"issue":"9","key":"462_CR20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-4632.2004.02124.x","volume":"43","author":"AC Halpern","year":"2004","unstructured":"Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol. 2004;43(9):638\u201342.","journal-title":"Int J Dermatol."},{"key":"462_CR21","unstructured":"Del Rosso JQ, Kircik L, Goldenberg G, Brian B. Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach. J Clin Aesthet Dermatol. 2014;7(9 Suppl S2\u2013S12):S2\u2013S12."},{"issue":"5","key":"462_CR22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1590\/abd1806-4841.20132300","volume":"88","author":"LA Torezan","year":"2013","unstructured":"Torezan LA, Festa-Neto C. Cutaneous field cancerization: clinical, histopathological and therapeutic aspects. An Bras Dermatol. 2013;88(5):775\u201386.","journal-title":"An Bras Dermatol."},{"key":"462_CR23","first-page":"4415","volume":"12","author":"AK Gupta","year":"2012","unstructured":"Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:4415.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"462_CR24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjd.12343","volume":"169","author":"AK Gupta","year":"2013","unstructured":"Gupta AK, Paquet M. Network meta-analysis of the outcome \u2018participant complete clearance\u2019 in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013;169(2):250\u20139.","journal-title":"Br J Dermatol."},{"key":"462_CR25","unstructured":"Picato (ingenol mebutate) [package insert]. Parsippany, NJ: LEO Pharma; 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202833lbl.pdf . Accessed 26 June 2016."},{"key":"462_CR26","unstructured":"Picato (ingenol mebutate). European Medicines Agency; 2012. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002275\/human_med_001600.jsp&mid=WC0b01ac058001d124\/ . Accessed 26 June 2016."},{"issue":"3","key":"462_CR27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2010.12.038","volume":"66","author":"RH Rosen","year":"2012","unstructured":"Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486\u201393.","journal-title":"J Am Acad Dermatol."},{"issue":"11","key":"462_CR28","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","volume":"366","author":"M Lebwohl","year":"2012","unstructured":"Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010\u20139.","journal-title":"N Engl J Med."},{"issue":"10","key":"462_CR29","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.ad.2015.04.010","volume":"106","author":"A Batalla","year":"2015","unstructured":"Batalla A, Florez A, Feal C, Peon G, Abalde MT, Salgado-Boquete L, et al. Clinical response to ingenol mebutate in patients with actinic keratoses. Actas Dermosifiliogr. 2015;106(10):e55\u201361.","journal-title":"Actas Dermosifiliogr."},{"issue":"11","key":"462_CR30","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jdv.13180","volume":"29","author":"RN Werner","year":"2015","unstructured":"Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis\u2014International League of Dermatological Societies in cooperation with the European Dermatology Forum\u2014Short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069\u201379.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"462_CR31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00019053-200927060-00002","volume":"27","author":"MV Neidecker","year":"2009","unstructured":"Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009;27(6):451\u201364.","journal-title":"Pharmacoeconomics."},{"key":"462_CR32","unstructured":"Agency for Healthcare Research and Quality, 2016. http:\/\/www.ahrq.gov\/ . Accessed 8 May 2016."},{"key":"462_CR33","unstructured":"American Academy of Dermatology, 2016. http:\/\/www.aad.org\/ . Accessed 8 May 2016."},{"issue":"2","key":"462_CR34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00019053-200422020-00002","volume":"22","author":"MK Higashi","year":"2004","unstructured":"Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics. 2004;22(2):83\u201394.","journal-title":"Pharmacoeconomics."},{"issue":"7","key":"462_CR35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamadermatol.2016.0502","volume":"152","author":"JS Kirby","year":"2016","unstructured":"Kirby JS, Delikat A, Leslie D, Miller JJ. Bundled payment models for actinic keratosis management. JAMA Dermatol. 2016;152(7):789\u201397.","journal-title":"JAMA Dermatol."},{"issue":"11","key":"462_CR36","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","volume":"28","author":"EC Wilson","year":"2010","unstructured":"Wilson EC. Cost effectiveness of imiquimod 5\u00a0% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics. 2010;28(11):1055\u201364.","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"462_CR37","first-page":"573","volume":"145","author":"GL Colombo","year":"2010","unstructured":"Colombo GL, Chimenti S, Di Matteo S, Fargnoli MC, Frascione P, Silipo V, et al. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. G Ital Dermatol Venereol. 2010;145(5):573\u201381.","journal-title":"G Ital Dermatol Venereol."},{"issue":"5","key":"462_CR38","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/bjd.12844","volume":"170","author":"C Zane","year":"2014","unstructured":"Zane C, Facchinetti E, Rossi MT, Specchia C, Calzavara-Pinton PG. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3\u00a0% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol. 2014;170(5):1143\u201350.","journal-title":"Br J Dermatol."},{"key":"462_CR39","doi-asserted-by":"publisher","unstructured":"Nistico S, Torchia V, Gliozzi M, Bottoni U, Del Duca E, Muscoli C. Pharmacoeconomy of drugs used in the treatment of actinic keratoses. Int J Immunopathol Pharmacol. doi: 10.1177\/0394632016648707 . (Epub 11 May 2016).","DOI":"10.1177\/0394632016648707"},{"issue":"3","key":"462_CR40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/14737167.2015.995171","volume":"15","author":"D Nieves","year":"2015","unstructured":"Nieves D, Puig-Peiro R, Ferrandiz C, Plazas MJ, Brosa M. Cost-effectiveness analysis of 5-fluorouracil 0.5%\/salicylic acid 10% in the treatment of actinic keratosis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):539\u201343.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"6","key":"462_CR41","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ad.2016.03.004","volume":"107","author":"I Elias","year":"2016","unstructured":"Elias I, Ortega-Joaquin N, de la Cueva P, Del Pozo LJ, Moreno-Ramirez D, Boada A, et al. Cost-effectiveness and cost-utility analysis of ingenol mebutate versus diclofenac 3\u00a0% and imiquimod 5\u00a0% in the treatment of actinic keratosis in Spain. Actas Dermosifiliogr. 2016;107(6):498\u2013508.","journal-title":"Actas Dermosifiliogr."},{"issue":"5","key":"462_CR42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12325-015-0211-7","volume":"32","author":"EJ Soini","year":"2015","unstructured":"Soini EJ, Hallinen T, Sokka AL, Saarinen K. Cost-utility of first-line actinic keratosis treatments in Finland. Adv Ther. 2015;32(5):455\u201376.","journal-title":"Adv Ther."},{"issue":"2","key":"462_CR43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2340\/00015555-2205","volume":"96","author":"N Neittaanmaki-Perttu","year":"2016","unstructured":"Neittaanmaki-Perttu N, Gronroos M, Karppinen T, Snellman E, Rissanen P. Photodynamic therapy for actinic keratoses: a randomized prospective non-sponsored cost-effectiveness study of daylight-mediated treatment compared with light-emitting diode treatment. Acta Derm Venereol. 2016;96(2):241\u20134.","journal-title":"Acta Derm Venereol."},{"issue":"3","key":"462_CR44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-2216","volume":"96","author":"MC Rijsingen van","year":"2016","unstructured":"van Rijsingen MC, Seubring I, Grutters JP, Maessen-Visch MB, Alkemade HA, van Doorn R, et al. Real-life data on patient characteristics, cost and effectiveness of field-directed treatment for actinic keratoses: an observational study. Acta Derm Venereol. 2016;96(3):346\u201350.","journal-title":"Acta Derm Venereol."},{"issue":"3","key":"462_CR45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10198-015-0679-8","volume":"17","author":"K Tolley","year":"2016","unstructured":"Tolley K, Kemmett D, Thybo S, Nasr R, Smethurst H. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective. Eur J Health Econ. 2016;17(3):287\u2013304.","journal-title":"Eur J Health Econ."},{"issue":"7","key":"462_CR46","doi-asserted-by":"crossref","first-page":"A422","DOI":"10.1016\/j.jval.2015.09.564","volume":"18","author":"K Athanasakis","year":"2015","unstructured":"Athanasakis K, Boubouchairopoulou N, Tarantilis F, Tsiantou V, Kontodimas S, Kyriopoulos J. Cost-effectiveness analysis of topical filed treatment therapies for the treatment of actinic keratosis in Greece. Value Health. 2015;18(7):A422.","journal-title":"Value Health."},{"issue":"7","key":"462_CR47","doi-asserted-by":"crossref","first-page":"A608","DOI":"10.1016\/j.jval.2014.08.2126","volume":"17","author":"S Matteo Di","year":"2014","unstructured":"Di Matteo S, Colombo GL, Pellacani G, Bruno GM. Cost-effectiveness analysis of ingenolo mebutato verse imiquimod in the treatment of actinic keratoses in the perspective of the Italian Health System. Value Health. 2014;17(7):A608.","journal-title":"Value Health."},{"issue":"7","key":"462_CR48","doi-asserted-by":"crossref","first-page":"A423","DOI":"10.1016\/j.jval.2015.09.569","volume":"18","author":"N Ortega-Joaquin","year":"2015","unstructured":"Ortega-Joaquin N, Elias I, de la Cueva P, Del Pozo LJ, Boada A, Moreno D, et al. Cost-utility analysis of ingenol mebutate versus imiquimod 5\u00a0% for actinic keratosis treatment in Spain. Value Health. 2015;18(7):A423.","journal-title":"Value Health."},{"issue":"6","key":"462_CR49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/0272989X03259817","volume":"23","author":"B Littenberg","year":"2003","unstructured":"Littenberg B, Partilo S, Licata A, Kattan MW. Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med Decis Making. 2003;23(6):480\u20138.","journal-title":"Med Decis Making."},{"issue":"2","key":"462_CR50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1087-0024.2003.09112.x","volume":"9","author":"SC Chen","year":"2004","unstructured":"Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Invest Dermatol Symp Proc. 2004;9(2):160\u20138.","journal-title":"J Invest Dermatol Symp Proc."},{"key":"462_CR51","doi-asserted-by":"publisher","unstructured":"Foley P, Stockfleth E, Peris K, Basset-Seguin N, Cerio R, Antonio Sanches J, et al. Adherence to topical therapies in actinic keratosis: a literature review. J Dermatol Treat. doi: 10.1080\/09546634.2016.1178372 . (Epub 10 May 2016).","DOI":"10.1080\/09546634.2016.1178372"},{"key":"462_CR52","first-page":"35","volume":"8","author":"B Shergill","year":"2013","unstructured":"Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adher. 2013;8:35\u201341.","journal-title":"Patient Prefer Adher."},{"key":"462_CR53","doi-asserted-by":"publisher","unstructured":"Erntoft S, Norlin JM, Pollard C, Diepgen TL. Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study. Br J Dermatol. doi: 10.1111\/bjd.14680 . Epub 18 Apr 2016.","DOI":"10.1111\/bjd.14680"},{"issue":"2","key":"462_CR54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2008.562","volume":"145","author":"B Yentzer","year":"2009","unstructured":"Yentzer B, Hick J, Williams L, Inabinet R, Wilson R, Camacho FT, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5\u00a0%, cream for the treatment of actinic keratoses. Arch Dermatol. 2009;145(2):203\u20135.","journal-title":"Arch Dermatol."},{"issue":"5","key":"462_CR55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/ijd.12840","volume":"54","author":"E Stockfleth","year":"2015","unstructured":"Stockfleth E, Peris K, Guillen C, Cerio R, Basset-Seguin N, Foley P, et al. A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. Int J Dermatol. 2015;54(5):509\u201315.","journal-title":"Int J Dermatol."},{"issue":"1","key":"462_CR56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0190-9622(99)70526-8","volume":"40","author":"SR Feldman","year":"1999","unstructured":"Feldman SR, Fleischer AB Jr, Williford PM, Jorizzo JL. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol. 1999;40(1):43\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"462_CR57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/jdv.12530","volume":"29","author":"E Stockfleth","year":"2015","unstructured":"Stockfleth E, Peris K, Guillen C, Cerio R, Basset-Seguin N, Foley P, et al. Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29(2):298\u2013306.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3","key":"462_CR58","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/09546630600765081","volume":"17","author":"R Balkrishnan","year":"2006","unstructured":"Balkrishnan R, Cayce KA, Kulkarni AS, Orsagh T, Gallagher JR, Richmond D, et al. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatol Treat. 2006;17(3):162\u20136.","journal-title":"J Dermatol Treat."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-016-0462-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T14:26:23Z","timestamp":1657549583000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-016-0462-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["462"],"URL":"https:\/\/doi.org\/10.1007\/s40273-016-0462-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]}}}